

Filed On Behalf Of:
Novartis AG

By:
Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

Case IPR2016-00084

Patent No. 5,665,772

PATENT OWNER'S EXHIBIT LIST 2

Exhibit	Description	Abbreviation
2001	Mason J., "Cyclosporins Past, Present, and Future," <i>Transplant. Proc.</i> 24(4) (Suppl. 2):61-63 (1992)	Mason
2002	Wenk, M. <i>et al.</i> , "Pharmacokinetics of Cyclosporine G in Patients with Renal Failure," <i>Transplantation</i> 45(3):558-61 (1988)	Wenk
2003	Traber, R. <i>et al.</i> , "Cyclosporins—New Analogues by Precursor Directed Biosynthesis," <i>Journal of Antibiotics</i> 42(4):591-97 (1989)	Traber
2004	Borel, J., "The Cyclosporins," <i>Transplant. Proc.</i> 21(1):810-15 (1989)	Borel
2005	Rozycki, J. <i>et al.</i> , "New Cyclosporin A Analogue: Synthesis and Immunosuppressive Activity," <i>Molecular Immunology</i> 29(9):1043-47 (1992)	Rozycki
2006	U.S. Patent No. 4,764,503	'503 patent
2007	U.S. Patent No. 4,885,276	'276 patent
2008	U.S. Patent No. 5,116,816	'816 patent
2009	U.S. Patent No. 5,122,511	'511 patent

Exhibit	Description	Abbreviation
2010	Rosen, M. & Schreiber, S., "Natural Products as Probes of Cellular Function: Studies of Immunophilins," <i>Angew. Chem. Int. Ed. Engl.</i> 31:384-400 (1992)	Rosen
2011	Fagioli, S. <i>et al.</i> , "FK 506: A New Immunosuppressive Agent for Organ Transplantation. Pharmacology, Mechanism of Action and Clinical Applications," <i>Ital. J. Gastroenterol.</i> 24(6):355-60 (1992)	Fagioli
2012	Keeffe, E. B., "Liver Transplantation—Challenges for the Future," <i>Western Journal of Medicine</i> 155(5):541-44 (1991)	Keeffe
2013	U.S. Patent No. 5,068,323	'323 patent
2014	U.S. Patent No. 4,980,466	'466 patent
2015	U.S. Patent No. 5,143,918	'918 patent
2016	U.S. Patent No. 4,929,611	'611 patent
2017	U.S. Patent No. 5,011,844	'844 patent
2018	EP 0 427 680	EP 680
2019	Carpenter, C. B., "Immunosuppression in Organ Transplantation," <i>New Eng. J. Med.</i> 322(17):1224-26 (1990)	Carpenter

Exhibit	Description	Abbreviation
2020	Parlevliet, K. J. & Schellekens, P. T. A., "Monoclonal Antibodies in Renal Transplantation: A Review," <i>Transplant. Int.</i> 5(4):234-46 (1992)	Parlevliet
2021	Cramer, D. V. <i>et al.</i> , "The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and Kidney Allograft Rejection in the Rat," <i>Transplantation</i> , 53(2):303-08 (1992)	Cramer
2022	Bartlett, R. R. <i>et al.</i> , "Leflunomide (HWA 486), a Novel Immunomodulating Compound for the Treatment of Autoimmune Disorders and Reactions Leading to Transplantation Rejection," <i>Agents and Actions</i> 32(1/2):10-21 (1991)	Bartlett
2023	Sollinger, H. W. <i>et al.</i> , "RS-61443 (Mycophenolate Mofetil): A Multicenter Study for Refractory Kidney Transplant Rejection," <i>Ann. Surg.</i> 216(4):513-19 (1992)	Sollinger
2024	Mita K. <i>et al.</i> , "Advantages of Mizoribine Over Azathioprine in Combination Therapy With Cyclosporine for Renal Transplantation," <i>Transplant. Proc.</i> 22(4):1679-81 (1990)	Mita

Exhibit	Description	Abbreviation
2025	Iino, Y. <i>et al.</i> , “Improvement of Renal Function in Transplanted Kidneys with a New Immunosuppressive Drug, 15-Deoxyspergualin: Treatment of Chronic Rejection,” <i>Transplant. Proc.</i> 24(4):1381-82 (1992)	Iino
2026	U.S. Patent No. 4,952,579	'579 patent
2027	U.S. Patent No. 5,061,787	'787 patent
2028	U.S. Patent No. 5,137,917	'917 patent
2029	EP 0 181 592	EP 592
2030	U.S. Patent No. 4,847,381	'381 patent
2031	U.S. Patent No. 4,968,701	'701 patent
2032	Aulton, M. E. (Ed.), Chapters 3, 6, 8, 14, <i>Pharmaceutics: The Science of Dosage Form Design</i> (1988)	Aulton
2033	Silverman, R.B., Chapter 8, “Prodrugs and Drug Delivery Systems,” <i>The Organic Chemistry of Drug Design and Drug Action</i> (1992)	Silverman

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.